Justicia oncodes

FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

Retrieved on: 
Wednesday, May 18, 2022
Ruxolitinib, Multiple myeloma, Death, Risk, Fever, Lymphatic system, Spleen, MC, Justicia oncodes, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Infection, Survival, Erasmus, Incidence, Bone marrow failure, Nasdaq, Patient, Erasmus MC, EU, NASDAQ, MF, Acute leukemia, Erythropoietin, Therapy, Degenerative disease, Trial of the century, Research, FDA, Haematopoietic system, JAK, Partnership, Laquinimod, Fibrosis, Biotechnology, III, Anemia, CET, ACTI, CFO, Pancreatic serous cystadenoma, CEO, Pharmaceutical industry

Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.

Key Points: 
  • Lund May 18, 2022 - Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.
  • The Orphan Drug Designation awarded by the FDA for tasquinimod in myelofibrosis represents an important step forward for Active Biotech, said Heln Tuvesson, CEO Active Biotech.
  • The FDA Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnoses or prevention of rare diseases or disorders that affects fewer than 200,000 people in the U.S.
  • Active Biotech and Erasmus MC have initiated a research collaboration with tasquinimod in myelofibrosis, that includes preclinical studies as well as a clinical proof of concept study in patients with myelofibrosis.

Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis

Retrieved on: 
Wednesday, February 9, 2022
NASDAQ, CFO, Multiple myeloma, Trial of the century, Erasmus, Laquinimod, Patent, III, Ruxolitinib, ACTI, Naptumomab estafenatox, Pancreatic serous cystadenoma, Marketing, Lymphatic system, Infection, Incidence, Therapy, Justicia oncodes, MC, Risk, Erythropoietin, Patient, Spleen, Survival, Anemia, Haematopoietic system, Acute leukemia, CEO, CET, Bone marrow failure, Death, Biotechnology, Erasmus MC, Fever, Disease, EU, Partnership, Bone marrow, Fibrosis, JAK, Pharmaceutical industry, MF

Under the terms of the agreement, Oncode Institute, a foundation incorporated under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum (Erasmus MC), grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Active Biotech.

Key Points: 
  • Under the terms of the agreement, Oncode Institute, a foundation incorporated under the laws of the Netherlands, acting on behalf of Erasmus Universiteit Medisch Centrum (Erasmus MC), grants a global exclusive license to develop and commercialize tasquinimod worldwide in MF to Active Biotech.
  • Active Biotech will pay to Oncode Institute, contingent of marketing approval, milestones as well as low single-digit royalties on net sales.
  • The results suggest that tasquinimod can act as a disease modifying agent in MF.
  • Active Biotech and Erasmus MC will initiate a research collaboration related to use of tasquinimod in MF, that includes preclinical as well as a clinical proof of concept study in patients with MF.

Oncode Institute and ArgoBio Launch Laigo Bio, a Targeted Protein Degradation Biotech With Programs in Oncology and Neurological Disorders

Retrieved on: 
Tuesday, February 8, 2022
Other Professional Services, Other Health, Stem Cells, Finance, Pharmaceutical, Oncology, General Health, Professional Services, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Science, Research, Health, Valorisation, Bridges Fund Management, Growth, IO, UMC, Science, Research, Dutch Cancer Society, Cancer, University Medical Center Utrecht, Quality of life, Patient, WNT, Diagnosis, Lists of diseases, Hospital, Cell membrane, Principal investigator, Therapy, Biology, Education, Economy, Pharmaceutical industry, Collaboration, Justicia oncodes, Health, Argobio:, Oncode Institute, Oncode Bridge Fund, UMC Utrecht:, Laigo Bio, ARGOBIO:, ONCODE INSTITUTE, ONCODE BRIDGE FUND, UMC UTRECHT:, LAIGO BIO

ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice , researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation.

Key Points: 
  • ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice , researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation.
  • The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR.
  • The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of disease applications.
  • The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases.

Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100

Retrieved on: 
Wednesday, January 12, 2022
Securities Exchange Act of 1934, Patient, Research, NKI, Netherlands Cancer Institute, CA, NASDAQ, Dias, CEO, Justicia oncodes, GLOBE, Cancer, U.S. Securities and Exchange Commission, Marketing, PP2A, Company, MD, Toxicity, Patent, Cell, Drug Quality and Security Act, Securities Act of 1933, Terminology, Pharmaceutical industry

Lixte, NKI and Oncode Institute believe that the combination therapy would provide unexpectedly strong synergisticanti-cancer effects in cancer patients.

Key Points: 
  • Lixte, NKI and Oncode Institute believe that the combination therapy would provide unexpectedly strong synergisticanti-cancer effects in cancer patients.
  • This paradoxicalintervention is truly groundbreaking and may be applicable to a broad range of cancers."
  • LB-100 is being tested in three clinical cancer treatment studies, with others in planning.
  • This discussion should be read in conjunction with the Company's filings with the United States Securities and Exchange Commission at sec.gov/edgar.shtml.

DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther

Retrieved on: 
Wednesday, October 20, 2021
Netherlands Cancer Institute, Biology, Dutch Cancer Society, MAP2K4, MAP, All European Academies, Colorectal cancer, Diagnosis, KRAS, Translational research, News, MEK, Valorisation, MKK4, DGAP, Cancer research, Research, Cancer Science, Liver regeneration, Quality of life, Justicia oncodes, Hepatocyte, Patient, Economy, Novo Holdings A/S, Cancer, Pharmaceutical industry, HepaRegeniX GmbH -, the Oncode Institute, Utrecht, HEPAREGENIX GMBH -, THE ONCODE INSTITUTE, UTRECHT

MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.

Key Points: 
  • MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
  • This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
  • Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
  • About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
    The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.

Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment

Retrieved on: 
Wednesday, October 13, 2021
Cancer Science, Death, Cell, Technology, Professor, Securities Exchange Act of 1934, Drug combination, Diagnosis, Terminology, Genome, Cancer, NKI, Valorisation, Dutch Cancer Society, Netherlands Cancer Institute, PP2A, BRAF, Nature, Neoplasm, Securities Act of 1933, Marketing, FDA, Drug Quality and Security Act, Economy, Patient, Biology, GLOBE, U.S. Securities and Exchange Commission, Toxicity, Company, European Academy of Allergy and Clinical Immunology, EGFR, CEO, Research, CA, Quality of life, Justicia oncodes, Liver cancer, Pharmaceutical industry

Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.

Key Points: 
  • Its ubiquitous activity and low toxicity have made it challenging to select the most promising clinical targets for this novel compound.
  • Professor Bernards commented, We are excited to work with Lixte to identify the most powerful drug combinations of LB-100 for cancer therapy.
  • Our unbiased genetic approach to identify synthetic lethal drug targets of LB-100 has proven its utility in our previous studies.
  • www.lixte.com
    About the Netherlands Cancer Institute, Amsterdam
    The Netherlands Cancer Institute , founded in 1913, is among the worlds best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.